Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD34+ cell therapy for inoperable peripheral arterial disease
ACTRN12611000011987Phase 2Withdrawn
- Sponsor
- The Alfred Hospital
- Start
- Jan 2011
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of CD34+ hematopoietic progenitor cells in arteriosclerosis obliterans (2 arms), sponsored by The Alfred Hospital. Primary endpoint: Change in ankle-brachial index. Planned start Jan 2011; status: withdrawn.
02
Drugs
CD34+ hematopoietic progenitor cells
03
Conditions
arteriosclerosis obliterans
Beyond the preview
Go deeper on ACTRN12611000011987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000011987.